Biologics Laboratory
Since May 2023, a newly established National Control Laboratory (NCL) – Biologics Laboratory has started operation in HSA to conduct testing on biological therapeutic products derived from biological systems to assure the quality and safety of their use. The product types include but are not limited to vaccines, monoclonal antibodies, blood derivatives and recombinant biological products.
The main scope of our work is to support the Health Products Act and Medicines Act through the conduct of post-market product quality surveillance testing, provision of expert opinions to support regulatory activities in the import of vaccines for the local market as well as to perform lot release of locally manufactured vaccines.